Marije Van Schalkwyk

Years Active: 2022-2023
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Marije Van Schalkwyk, Adrie Bekker, Eric Decloedt, Jiajia Wang, Gerhard B Theron, Mark F Cotton, Ahizechukwu C Eke, Tim R Cressey, David E Shapiro, Kira Bacon, Kevin Knowles, Kathleen George, Renee Browning, Nahida Chakhtoura, Kittipong Rungruengthanakit, Lubbe Wiesner, Edmund V Capparelli, Alice M Stek, Mark Mirochnick, Brookie M Best, null null
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Antimicrobial agents and chemotherapy (2023)
Anchalee Avihingsanon, Michael D Hughes, Robert Salata, Catherine Godfrey, Caitlyn McCarthy, Peter Mugyenyi, Evelyn Hogg, Robert Gross, Sandra W Cardoso, Aggrey Bukuru, Mumbi Makanga, Sharlaa Badal-Aesen, Vidya Mave, Beatrice Wangari Ndege, Sandy Nerette Fontain, Wadzanai Samaneka, Rode Secours, Marije Van Schalkwyk, Rosie Mngqibisa, Lerato Mohapi, Javier Valencia, Patcharaphan Sugandhavesa, Esmelda Montalban, Cornelius Munyanga, Maganizo B Chagomerana, Breno R Santos, Nagalingeswaran Kumarasamy, Cecilia Kanyama, Robert T Schooley, John W Mellors, Carole L Wallis, Ann C Collier, Beatriz Grinsztejn, null null
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. Journal of the International AIDS Society 25 (6) (2022)

Marije Van Schalkwyk.css-eqlu8i{font-size:small;padding-left:4px;}